Bismuth Neurotoxicity from Use of Topical Bismuth Dressing for Burns
Neurol 92:680-681, Saini, V.,et al, 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
NEJM 380:1597-1605, Cortese, I.,et al, 2019
Clinicopathologic Conference, Ingestion of Isopropyl Alcohol
NEJM 380:1657-1665, Case 13-2019, 2019
Magnetic Resonance Imaging Versus Computed Tomography Angiography Based Selection for Endovascular Therapy in Patients with Acute Ischemic Stroke
Stroke 50:365-372, Kim, J-T.,et al, 2019
Cholesterol Lowering and Prevention of Stroke
Stroke 50:537-541, Hackam, D.G. & Hegele, R.A., 2019
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
NEJM 380:1795-1803,1865, Ma, H.,et al, 2019
Recommendations for the Establishment of Stroke Systems of Care
Stroke 50:e1-e24, Adeoye, O.,et al, 2019
Imaging Findings After Mechanical Thrombectomy in Acute Ischemic Stroke
Stroke 50:1618-1625, Puntonet, J.,et al, 2019
Impact of Microbleeds on Outcome Following Recanalization in Patients with Acute Ischemic Stroke
Stroke 50:127-134, Choi, K.H.,et al, 2019
The Dangers of PRES
Neurol 92:e282-e285, Chaterine, C.,et al, 2019
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Rapid Progression of Reversible Cognitive Impairment in an 80-year-old Man
Neurol 91:1109-1113, Bouthour, W.,et al, 2018
Spinal Cord Infarction Because of Spontaneous Vertebral Artery Dissection
Stroke 49:e314-e317, Montalvo, M.,et al, 2018
White Matter Lesion Related to Decompression Sickness Following Extreme Breath-Hold Diving
Neurol 91:847-848, Guerreiro, C.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Hearing and Vision Loss in an Older Man
JAMA Neurol 75:1439-1440, Ho, V.M.,et al, 2018
Surviving Cerebral Malaria
Neurol 91:978-979, Wijdicks, E.F.M. & Park, J.G., 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Implications of the WAKE-UP Trial
Stroke 49:3115-3117, Silver, B. & Arnold, M., 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Selenium Toxicity Associated with Reversible Leukoencephalopathy and Cortical Blindness
JAMA Neurol 75:1282-1283, Rae, W.,et al, 2018
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Interventions for Improving Modifiable Risk Factor Control in the Secondary Prevention of Stroke
Stroke 49:e301-e302, Bridgwood, B.,et al, 2018
Mechanical Thrombectomy Outcomes with or without Intravenous Thrombolysis
Stroke 49:2383-2390, Gariel, F.,et al, 2018
Endovascular Stroke Therapy in the Late Time Window
Stroke 49:2559-2561, Schellinger, P.D. & Demaerschalk, B.M., 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
NEJM 378:708-718, Albers, G.W.,et al, 2018
2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke
Stroke 49:e46-e110, Powers, W.J.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
A 56-year-old woman with acute vertigo and diplopia
Neurol 90:748-752, Sharma, R.,et al, 2018
Toxidrome Recognition in Chemical - Weapons Attacks
NEJM 378:1611-1620, Ciottone, G.R., 2018
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
NEJM 378:1573-1582, Campbell, B.C.V.,et al, 2018
Automated DWI analysis can identify patients within the thrombolysis time window of 4.5 hours
Neurol 90:e1570-e1577, Wouters, A.,et al, 2018
Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018
Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants with Serotonin Syndrome
JAMA Neurol 75:566-572, Orlova, Y.,et al, 2018
A 77-year-old man presenting with episodic expressive aphasia
Neurol 90:e1822-e1826, Shanklin, A.,et al, 2018
Time to Decision and Treatment with tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit
Stroke 49:1528-1530, Bowry, R.,et al, 2018
Magnetic Resonance Imaging Selection for Endovascular Stroke Therapy
Stroke 49:1402-1406, Simonsen, C.Z.,et al, 2018
Diagnosis and Management of Active Intracranial Atherosclerotic Disease
Stroke 49:e221-e223, Narwal, P.,et al, 2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018